Investing Profile

Mark Sullivan

InvestorVC
Venture Partner at Adjuvant Capital
adjuvantcapital.com/team/Melbourne, Australia
Photo of Mark Sullivan, Venture Partner at Adjuvant Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
GSK Network
45 CONNECTIONS
Gilead Sciences Network
20 CONNECTIONS
GlaxoSmithKline Network
19 CONNECTIONS
Adjuvant Capital Venture Partner
$100K - $5.0M
$1.5M
$300M
Research Scientist Johnson MattheyPresent
Clinical Program Head GlaxoSmithKlinePresent
Clinical Program Head GSKPresent
Director, Asia Pacific i3 ResearchPresent
Associate Director, Clinical Research Gilead SciencesPresent
Managing Director Medicines Development for Global HealthPresent
Lecturer Melbourne Business SchoolPresent
Honorary Professor UNSW Civil and Environmental EngineeringPresent
Senior Advisor Global Health FundsPresent
Venture Partner Adjuvant CapitalPresent
Sign in with Google →
Sign in with Google →